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The vector-borne disease leishmaniasis is transmitted to humans by infected female sand
flies, which transmits Leishmania parasites together with saliva during blood feeding. In
Iran, cutaneous leishmaniasis (CL) is caused by Leishmania (L.) major and L. tropica, and
their main vectors are Phlebotomus (Ph.) papatasi and Ph. sergenti, respectively. Previous
studies have demonstrated that mice immunized with the salivary gland homogenate (SGH)
of Ph. papatasi or subjected to bites from uninfected sand flies are protected against L.
major infection.
Methods and results
In this work we tested the immune response in BALB/c mice to 14 different plasmids coding
for the most abundant salivary proteins of Ph. sergenti. The plasmid coding for the salivary
protein PsSP9 induced a DTH response in the presence of a significant increase of IFN-γ
expression in draining lymph nodes (dLN) as compared to control plasmid and no detectable
PsSP9 antibody response. Animals immunized with whole Ph. sergenti SGH developed
only a saliva-specific antibody response and no DTH response. Mice immunized with whole
Ph. sergenti saliva and challenged intradermally with L. tropica plus Ph. sergenti SGH in
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their ears, exhibited no protective effect. In contrast, PsSP9-immunized mice showed pro-
tection against L. tropica infection resulting in a reduction in nodule size, disease burden
and parasite burden compared to controls. Two months post infection, protection was asso-
ciated with a significant increase in the ratio of IFN-γ to IL-5 expression in the dLN compared
to controls.
Conclusion
This study demonstrates that while immunity to the whole Ph. sergenti saliva does not
induce a protective response against cutaneous leishmaniasis in BALB/c mice, PsSP9, a
member of the PpSP15 family of Ph. sergenti salivary proteins, provides protection against
L. tropica infection. These results suggest that this family of proteins in Ph. sergenti, Ph.
duboscqi and Ph. papatasi may have similar immunogenic and protective properties against
different Leishmania species. Indeed, this anti-saliva immunity may act as an adjuvant to
accelerate the cell-mediated immune response to co-administered Leishmania antigens, or
even cause the activation of infected macrophages to remove parasites more efficiently.
These findings highlight the idea of applying arthropod saliva components in vaccination
approaches for diseases caused by vector-borne pathogens.
Author summary
Leishmaniasis is a vector-borne disease transmitted to humans by an infected sand fly
bite, through which Leishmania parasites and saliva are co-delivered into the host skin.
Despite the numerous studies performed in this area, no vaccine is yet available to control
this neglected disease in humans. During the past two decades, saliva of sand flies has
been tested for possible application as a vaccine against leishmaniasis. Exposure to specific
salivary proteins or sand fly bites can induce a protective cell-mediated immunity. Immu-
nization with Ph. papatasi saliva or recombinant PpSP15 has been previously reported to
provide protection against L. major infection. In this study, the efficiency of immunization
with Ph. sergenti saliva or plasmid coding for Ph. sergenti salivary proteins in protecting
the BALB/c mice against L. tropica was explored. Here we show that although immuniza-
tion with whole saliva induces a humoral response, this immune response is unable to
protect mice against infection; in contrast, immunization with a plasmid coding for Ph.
sergenti PsSP9 salivary protein induces a Th1 immune response characterized by a strong
DTH response, no detectable antibody response, and a high expression ratio of IFN-γ to
IL-5 in lymph nodes. The Th1 induced immunity in PsSP9-immunized mice correlates
with the protection observed against infection with L. tropica, which was associated with a
significant reduction in ear thickness and decrease in parasite load in the ear of protected
animals in comparison to control group. Our data suggest that instead of using the whole
sand fly salivary proteins, a more effective approach is the use of a single Ph. sergenti sali-
vary protein.
Introduction
As a vector-borne parasitic and tropical disease, leishmaniasis has been reported in 98 coun-
tries (in 4 continents) with an annual incidence level of 0.9–1.6 million individuals, and 350
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million individuals are at the risk of this infection [1,2]. The Leishmania parasite, as the causa-
tive agent of this disease, is delivered to the host during blood-feeding by infected female sand
flies, namely, the Phlebotomus species in the Old World (Asia, Africa and Europe) and the Lut-
zomyia species in the New World (Central and South America). Various clinical symptoms, in
visceral, mucocutaneus and cutaneous forms have been reported for leishmaniasis. The most
commonly observed type of this disease is CL, which results in ulcers and permanent scars on
the affected regions of the body and serious disabilities for the patient. Clinical forms of leish-
maniasis are geographically distributed depending on the availability of the pathogenic species
of Leishmania and their vectors. For example, CL has been mainly observed in Afghanistan,
Brazil, Iran, Iraq and Syrian Arab Republic [1]. The fact that infection with certain species,
including L. major or exposure to live Leishmania (leishmanization) results in long-term pro-
tection, in addition to the high costs of current treatments, drug toxicity and parasite resistance
emergence intensify the need for producing a vaccine for this disease [3–5]. However, despite
numerous investigations, no human vaccine for Leishmania is yet available [6].
Studies on development of Leishmania vaccines have focused on Leishmania antigens. In
the past two decades, researchers started to examine sand fly salivary proteins [7], which are
transmitted along with the parasite during blood feeding, as an alternative or a component of a
vaccine against leishmaniasis. Different molecules are present in sand fly saliva which alter the
hemostatic, inflammatory and immune response of the host, thereby facilitating parasite infec-
tion [8]. Simultaneous inoculation of Leishmania parasite and sand fly saliva has been reported
to increase the parasite burden and cause exacerbation of the generated lesions [7,9–12]. How-
ever, immunization of animals with salivary components [13–15] or salivary gland homoge-
nate (SGH) [12,16,17] from sand flies or exposing them to the bites of uninfected sand flies
[18–25] resulted in protection against infection with Leishmania [26]. A cell-mediated
immune response (CIR), as a form of a DTH response to sand fly salivary proteins, was shown
to provide protection against Leishmania infection. This anti-salivary immunity appears to be
important, considering that the parasite is unavoidably naturally injected along with salivary
proteins into the biting site. Hence, similar to an adjuvant, a Th1 anti-saliva immunity can
accelerate the induction of a protective Th1 immunity against Leishmania [27].
In Iran, zoonotic CL is caused by L. major, which is usually transmitted by the Ph. papatasi
vector. On the other hand, anthroponotic CL is caused by L. tropica mainly transmitted by the
Ph. sergenti sand fly [28]. According to the literature, exposing mice to the bites of uninfected
sand flies or immunizing them with Ph. papatasi SGH can protect them against L. major infec-
tion caused by needle inoculation [7] or the bites of infected sand flies [13]. Immunization
with PpSP15, a salivary protein from Ph. papatasi, provides protection in mice against L. major
infection [20,21,29,30]. The immunity induced by Ph. sergenti salivary proteins and their
effects on L. tropica infection have not been previously reported. Therefore, in this work, the
immunogenicity of Ph. sergenti salivary components were assessed and we tested whether
immunizing BALB/c mice with Ph. sergenti SGH or DNA plasmids coding for Ph. sergenti sali-
vary proteins can lead to an appropriate immunity to control L. tropica infection.
Materials and methods
Chemicals, media, reagents and instruments
Apyrogenic deionized water (Milli-Q System, Millipore, Molshem, France) was used to pre-
pare all needed solutions. The Endo-Free Plasmid Mega kit, RNeasy Mini Kit, Quanti Nova
SYBR Green Master Mix and Anti-His antibody were purchased from QIAGEN, Germany.
TRIzol Reagent and SuperScript III First-Strand Synthesis system were from Thermo Fisher
Scientific (Invitrogen Company, USA). The materials needed for PCR reaction, agarose gel
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electrophoresis and enzymatic digestion were all provided by Roche Applied Sciences, Ger-
many. Diaminobenzidine (DAB) powder, Bovine Serum Albumin (BSA) and acrylamide were
provided by Merck, Germany. Horseradish peroxidase-conjugated goat anti-mouse IgG, Urea,
Ponceau-S, Sodium dodecyl sulfate (SDS), Tris-base, Tris-HCL, M199 medium, RPMI-1640,
DMEM, gentamicin, kanamycin, L-glutamine, hemin, HEPES, adenosine and Ficoll-400 were
purchased from Sigma, Germany. Fetal Calf Serum (FCS) and Schneider insect media were
provided by Gibco (Life Technologies, Germany). Goat anti-mouse IgG1-HPR and IgG2-HPR
were obtained from Southern Biotech, Canada. Peroxidase Substrate System as an ELISA sub-
strate was from KPL (ABTS, USA). Linear Polyethylenimine was purchased from Polyscience,
Germany. Protran Nitrocellulose Transfer Membranes was from Schleicher & Schuell BioSci-
ence, Germany. GF-1 Tissue DNA Extraction Kit was purchased from Vivantis Technologies,
Malaysia. The Agilent RNA 6000 Nano reagent kit were purchased from Agilent Technologies,
USA. The Agilent 2100 Bioanalyzer instrument (Agilent Technologies, USA), ELISA reader
(Tecan, USA), NanoDrop (Nanodrop, ND-1000, USA) and Speed Vac (Thermo Scientific,
USA) devices were also used in this investigation.
Salivary gland homogenate (SGH) preparation
Ph. sergenti were kept in the insectary at the Laboratory of Malaria and Vector Research,
National Institutes of Health, NIH (Rockville, MD, USA). The salivary glands were dissected
from 5- to 7-day-old and non-blood fed female sand flies and then transferred to PBS for
subsequent storage at −70 ˚C. After disruption by ultra-sonication and centrifugation, the
produced supernatant was collected and dried in a Speed Vac device and reconstituted before
use.
Ethical statement
Female BALB/c mice, (6–8 weeks old) with weight range of 18–20 g were obtained from Pas-
teur Institute of Iran. The animals under investigation were maintained, handled, anesthetized
and euthanized under the approval of Institutional Animal Care and Research Advisory Com-
mittee of Pasteur Institute of Iran (ethical code: IR.RII.REC.1394.0201.6417, dated 2015). All
experiments were designed and carried out according to the Specific National Ethical Guide-
lines for Biochemical Research (2005) by the Research and Technology Deputy of Ministry of
Health and Medicinal Education (MOHM) of Iran. Mice were euthanized through cervical
dislocation method. Animals were anesthetized via intraperitoneal (i.p.) administration of
Xylazine/Ketamine anesthetizing cocktail [31] in order to minimize suffering animals under
investigation.
Preparation of plasmids encoding Ph. sergenti salivary proteins
The mammalian codon optimized nucleotides encoding the N-terminus to the stop codon of
the most abundant secreted proteins from Ph. sergenti salivary gland proteins were cloned in a
modified mammalian expression plasmid (VR1020-TOPO) through T/A cloning strategy and
topoisomerase technology and then transformed into the DH5α strain. The VR1020-TOPO
plasmid has features such as a CMV promoter, the signal-secretory peptide of tissue plasmino-
gen activator (TPA), replacing the sand fly specific-secretory signal peptide and a 6×His-tag,
downstream from the target insert. This modified vector enables efficient production of the
secreted proteins in animal tissues and other mammalian-based expression systems. The four-
teen cloned transcripts used in this study are PsSP7 (HM560864, D7-related proteins), PsSP9
(HM569364, PpSP15-like protein), PsSP14 (HM560870, PpSP15-like protein), PsSP15
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(HM560868, PpSP15-like protein), PsSP20 (HM560866, yellow-related proteins), PsSP26
(HM569362, yellow-related proteins), PsSP40 (HM560860, apyrase), PsSP41 (HM560862, apy-
rase), PsSP42 (HM560861, apyrase), PsSP44 (HM569368, PpSP32-like protein), PsSP52
(HM537134, antigen 5-related proteins), PsSP54 (HM569365, PpSP15-like protein), PsSP73
(HM569367, unknown), and PsSP98 (HM569366, unknown). In order to purify all recombi-
nant plasmids and the empty control plasmid (VR1020), an Endo-Free Plasmid Mega kit was
used according to the manufacturer’s protocol.
COS-7 cell transfection and confirmation of protein expression using
western blot analysis
In order to confirm the expression of the 14 plasmids harboring each Ph. sergenti salivary
protein, COS-7 cells (ATCC CRL-1651) were used as an expression host. Briefly, COS-7 cells
were cultured in six-well plates (Greiner) in complete RPMI medium supplemented with
10% FCS at 37 ˚C in the presence of 5% CO2. For cell transfection, we used PEI/DNA com-
plexes, prepared through mixing Linear Polyethylenimine (LINPEI, MW = 25 kDa, 10 μM)
and 5 μg of each recombinant plasmid or VR1020 (as the control) [32]. Expression of Ph. ser-
genti salivary proteins in transfected COS-7 cells were confirmed by western blot analysis. In
brief, forty eight hours after transfection, the supernatant of transfected COS-7 cells were
harvested, then mixed with SDS-PAGE sample buffer and boiled for 5 min, and run on a
12.5% or 15% SDS-PAGE gel. Proteins were then transferred from gel to nitrocellulose mem-
branes by electro-blotting. Free binding sites on nitrocellulose membrane were blocked with
blocking solution (PBS with 0.05% Tween 20 and 2.5% BSA) for 2 hours. After three washes,
the membrane was incubated with HRP-conjugated goat anti-mouse IgG (1:2000) for 2
hours at room temperature and visualized using the 3,30-diaminobenzidine substrate
(DAB).
Intradermal immunization with Ph. sergenti salivary DNA plasmids
In order to assess the immunogenic characteristics of DNA plasmids coding for Ph. sergenti
salivary proteins, 6–8 weeks old BALB/c mice (6 mice in each experimental group) were i.d.
immunized three times at two-week intervals using 30-gauge needle in the right ear. For this
purpose, we used 10 μg of plasmid (either the empty plasmid control or a recombinant plasmid
encoding a Ph. sergenti salivary protein), an equivalent of 0.5 Ph. sergenti salivary gland pair or
PBS; all in a total volume of ~10 μl with PBS.
Analysis of specific anti-saliva antibodies by ELISA
ELISA microplates were coated with 100 μl of SGH diluted to two pairs of SGHs/ml in coating
buffer (Na2CO3 0.02 M, NaHCO3 0.45 M, pH 9.6) overnight at 4 ˚C. Following rinsing with
PBS-0.05% Tween, wells were blocked using 100 μl of 1% BSA in PBS for 2 h at 37 ˚C. Wells
were incubated for 3 h with sera from mice immunized with recombinant or control plasmids
obtained two weeks after the last immunization and diluted (1:50) in PBS-0.05% Tween-1%
BSA. After one more washing step, wells were incubated with Horseradish peroxidase-conju-
gate goat anti-mouse IgG diluted (1:5000) in PBS-0.05% Tween-1% BSA for 2 h at 37 ˚C. Fol-
lowing another washing step, plates were incubated with Peroxidase Substrate System (KPL)
as the substrate for 30 min at 37 ˚C. After stopping the reactions with 1% SDS, the absorbance
was measured at 405 nm using an ELISA reader. The cut off value was determined by measur-
ing anti-saliva IgG of plasmid control mice group (mean + 3 SD).
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Analysis of DTH and histopathological assessment after immunization in
the ear dermis
Two weeks after the last step of immunization, the animals were inoculated i.d. into the left ear
dermis with Ph. sergenti SGH (0.5 salivary gland pair per mouse) using a 30-gauge needle.
Forty eight hours later, we measured ear thickness (DTH response) using a digital caliper
(with a resolution of 0.01 mm). For histopathological assessment at this time point, after fixing
the dissected ears in 10% phosphate-buffered formalin, they were processed, embedded in par-
affin, and then the 5-μm sections prepared by microtome were stained using hematoxylin and
eosin (H & E) and analyzed using light microscopy. For morphometric analyses, inflammatory
cells were counted in three fields/section using a 400× magnification, covering a total area of
710 mm2.
Immunization with Th1 DTH-inducing Ph. sergenti salivary DNA plasmid
and intradermal challenge with L. tropica parasites plus Ph. sergenti SGH
After screening the Th1 DTH response in BALB/c mice which was triggered by the saliva pro-
teins of Ph. Sergenti, the animals (10 mice per group) were immunized three times with two-
week intervals using the selected plasmid encoding Ph. sergenti salivary protein, SGH, empty
plasmid or PBS in the right ear using a 30-gauge needle. Two weeks after the last immuniza-
tion, animals were challenged i.d. into the left ear dermis with 107 metacyclic L. tropica para-
sites plus Ph. sergenti SGH (0.5 salivary gland pair) using a 30-gauge needle in an almost 10 μl
total volume. The L. tropica parasite named as MOHM/IR/09/Khamesipour-Mashhad was iso-
lated from patient in city of Mashhad, Iran, in 2009 (provided as gift by Dr. Ali Khamesipour).
L. tropica promastigotes were cultured in M199 medium supplemented with 10% hi-FCS. The
Ficoll-400 step-gradient was used to isolate the L. tropica metacyclic promastigotes [33]. To
mimic the natural model of infection and examine whether immunity to the salivary proteins
of the sand fly can protect the animals against CL, mice were infected by injection of parasites
together with Ph. sergenti SGH into their ear dermis. The ear thickness was monitored and
measured weekly using a digital caliper. To measure the disease burden (area under the curves,
AUC), the ear thickness of each individual immunized mouse was recorded once per week. A
disease course curve for each mouse in the experimental and control groups was separately
obtained. Prism (GraphPad Software) was used to calculate AUC.
Analysis of cytokine expression profile by Real-time PCR
Cytokine profiles were analyzed at two time points: once after Ph. sergenti SGH inoculation (to
screen the Th1 DTH response against each DNA plasmid), and once after infectious challenge
with L. tropica plus Ph. sergenti SGH. For this purpose, total RNA was extracted from the
mouse dLN using TRIzol reagent and then RNeasy Mini Kit. The quality of extracted RNA
was confirmed using an Agilent RNA 6000 Nano reagent kit. For first-strand cDNA synthesis,
approximately 2 μg of RNA reverse-transcribed in a total volume of 20 μl using SuperScript III
reverse transcriptase according to the manufacturer’s instructions. For quantification of gene
expression, the 1:10 diluted cDNA was subjected to the reaction containing 5 pmol of each for-
ward and reverse primer and 12.5 μl Quanti Nova SYBR Green Master Mix in a 25 μl total vol-
ume. Real-time PCR reactions were performed in duplicates on an Applied Biosystems 7500
instrument. Thermal cycles with an initial incubation step at 95 ˚C for 5 min followed by 45
cycles at 95 ˚C for 10 s, at 60 ˚C for 15 s, and at 72 ˚C for 35 s. The mRNA levels of each target
gene were normalized to that of HPRT. The results are shown in fold change compared to the
PBS control. Gene expression was analyzed based on the comparative method. The cycle
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threshold (Ct) values for cytokines were normalized to the expression of HPRT based on the
following formulation: ΔCt = Ct (target gene)−Ct (HPRT gene). We obtained the fold change using
2−ΔΔCt, in which ΔΔCt = ΔCt (test)−ΔCt (control) [34]. We used the following primers for real-
time PCR: HPRT (Forward: 50-GTCCCAGCGTCGTGATTAG-30; Reverse: 50-GAGCAAGTC
TTTCAGTCCTGTC-30); IFN-γ (Forward: 50-TCTGAGACAATGAACGCTACAC-30;
Reverse: 50-CTTCCACATCTATGCCACTTGAG-30); IL-5 (Forward: 50-TGACAAGCAATGA
GACGATGAG-30; Reverse: 50-CTCCAATGCATAGCTGGTGA-30).
Quantification of parasite propagation in the infected ear
Quantification of the parasites in the infected ear of animals in different groups was performed
using Real-time PCR at one and two months after challenge. After euthanizing animals in each
group (5 mice per group) the genomic DNA was extracted from each infected ear using GF-
1Tissue DNA Extraction Kit according to manufacturer’s instruction. DNA concentration was
measured by a NanoDrop device. The following primer set was used to target a part of L. tro-
pica kinetoplastid minicircle DNA: (KDNA1F: (5’-GGGTAGGGGCGTTCTGC-3’) and
KDNA1R (5’-TACACCAACCCCCAGTTTGC-3’)) [35,36]. The absolute copy number corre-
sponding to the target sequence was measured on an Applied Biosystems 7500 real time PCR
system. Standard L. tropica genomic DNA was used in 10-fold dilution corresponding to
2×108 to 2×101 parasites for drawing the standard curve. To quantify the parasites in tissues,
50 ng of DNA was applied to a reaction containing 5 pmol of each of the forward and reverse
primers and 12.5 μl of Quanti Nova SYBR Green Master Mix in a 25 μl total volume. The PCR
program was as the following: at 95 ˚C for 5 min; 40 cycles at 95 ˚C for 10 s, at 60 ˚C for 15 s,
and at 72 ˚C for 35 s. All reactions were performed in duplicate.
Statistical analysis
We replicated each measurement twice and averaged the obtained results. Shapiro-Wilk test
was used to check the distribution of DTH response, Antibody response, IFN-γ, IL-5 and ratio
of IFN-γ to IL-5 mRNA expression in dLN as well as parasite burden and disease burden (area
under the curves, AUC). Due to the non-normality of all data, non-parametric van der Waer-
den’s normal score test and Dunn’s multiple comparison tests were used to compare the distri-
bution of these variables between experimental and control group.
To assess the effect of variables on ear thickness, we used Linear Mixed Models for repeated
measured data. The significant interaction between time and group factors implied that the
experimental groups were changing with time, with different manners. A statistically signifi-
cant interaction effect may indicate that the overall patterns of differences at the level of main
effects are not likely to be consistent across all groups. The p values below 0.05 were considered
as significant. Statistical analyses were carried out using Stata (14.0) (StataCorp. 2015. Stata
Statistical Software: Release 14. College Station, TX: StataCorp LP) and R 3.4.3 (R Core Team
(2017). R: A language and environment for statistical computing. R Foundation for Statistical
Computing, Vienna, Austria) using the Rfit, PMCMR, nparcomp and multcomp packages.
Results
Confirmation of protein expression of all DNA constructs in COS-7 cell
Before screening the 14 different plasmids coding for Ph. sergenti salivary proteins in animals,
we tested the protein expressions of these DNA constructs in COS-7 cells. The construct has a
signal secretory peptide and we added to each transcript a histidine tag. We observed expres-
sion of protein in COS-7 cells from all plasmids (Fig 1).
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DNA encoding PsSP9 of Ph. sergenti salivary protein induces a Th1
response in immunized mice
The 14 different DNA plasmids coding for Ph. sergenti salivary proteins were screened to select
a plasmid that can induce a Th1 cellular immune response. We also compared these plasmids
to Ph. sergenti salivary gland homogenate. The parameters for selection were 1) The presence
of a distinct DTH response associated with mononuclear cell infiltration in the ear and 2)
increased levels of IFN-γ and low levels of IL-5 expression in dLN in comparison with the
empty plasmid control group. Surprisingly, immunization with the whole Ph. sergenti salivary
gland homogenate (SGH) did not induce a detectable DTH response (Fig 2A). In contrast,
seven plasmids induced a positive DTH and showed greater ear thickness than the control
plasmid that produced a median of 0.18 mm (Fig 2A). The median ranks of DTH responses
were in the following descending order: PsSP40 (0.26 mm), resulting in the greatest measur-
able response in animal skin; PsSP52 (0.24 mm), PsSP44 (0.23 mm), PsSP9 (0.23 mm), PsSP26
(0.22 mm), PsSP41 (0.22 mm) and PsSP42 (0.21 mm), as the smallest detectable levels. Groups
immunized with PsSP40 (p<0.01), PsSP52 (p<0.01), PsSP9 (p<0.01), PsSP44 (p<0.01),
PsSP26 (p<0.01), PsSP41 (p = 0.04) and PsSP42 (p = 0.03) showed significantly higher DTH
responses compared to the control plasmid (Fig 2A and S1 Table).
Specific total IgG antibody responses against Ph. sergenti SGH in the sera of all groups was
measured. In comparison with the control groups (PBS and VR1020), the Ph. sergenti SGH-
immunized mice group produced higher levels of anti-saliva-IgG than the cut off value
(median at OD405 nm = 0.40, S1 Table and Fig 2B). Moreover, the group immunized with
PsSP26-encoding plasmid had the highest level of total IgG antibody production against Ph.
sergenti SGH in comparison with the control plasmid group (median at OD405 nm = 1.53,
p<0.01). In addition, the two other groups encoding the PsSP7 and PsSP44 proteins also pro-
duced higher levels of total IgG than the cut off value (PsSP44 with median OD405 nm = 0.30,
p = 0.04 and PsSP7 with median OD405 nm = 0.45, p = 0.07) as demonstrated in Fig 2B and S1
Table.
Fig 1. Confirmation of Ph. sergenti salivary proteins expression in supernatant of COS-7 cell culture using western blot analysis by anti-His antibody. COS-7 cell
lines were transiently transfected with recombinant plasmids encoding for fourteen Ph. sergenti salivary proteins. Forty-eight h after transfection, the supernatants
were subjected to western blot analysis using anti-His antibody. Line 1. VR1020-PsSP7 (MW, 30.4 KDa), line 2. VR1020-PsSP9 (17.8 KDa), line 3. VR1020-PsSP20
(46.1 KDa), line 4. VR1020-PsSP42 (39.6 KDa), line 5. VR1020-PsSP52 (32.5 KDa), line 6. VR1020-PsSP54 (18.4 KDa), line 7. VR1020-PsSP40 (39.3 KDa), line 8.
VR1020-PsSP41 (37.4 KDa), line 9. VR1020-PsSP14 (20.8 KDa), line 10. VR1020-PsSP15 (18.4 KDa), line 11. VR1020-PsSP73 (16 KDa), line 12. VR1020-PsSP98 (18
KDa), line 13. VR1020-PsSP26 (46.2 KDa), line 14. VR1020-PsSP44 (24.8 KDa), line 15. VR1020.
https://doi.org/10.1371/journal.pntd.0007067.g001
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Based on histological analysis 48 h after Ph. sergenti SGH injection in the ear dermis of plas-
mid-immunized animals, PsSP9- and PsSP40-immunized groups were characterized by a
robust mononuclear infiltration mainly containing macrophages, lymphocytes and a lower
number of neutrophils compared to the PBS- and plasmid- control groups (Fig 3). The num-
ber of inflammatory cells recruited in the Ph. sergenti SGH-immunized mice group was mod-
erate and there were fewer cells than in the PsSP9- and PsSP40-immunized groups (Fig 3).
Furthermore, the number of inflammatory cells recruited in PsSP41- and PsSP52-immunized
mice was similar to that of Ph. sergenti SGH-immunized mice. No detectable increase in the
number of inflammatory cells recruited in PsSP42-immunized mice was observed, compared
to the PBS- and plasmid- control groups (Fig 3).
Based on the outcome of the DTH response, the antibody response (as shown in Table 1)
and histological analysis against various salivary proteins, PsSP9, PsSP40, PsSP41, PsSP42, and
PsSP52 plasmids were selected for further evaluation of the cellular immune response in
BALB/c mice.
Forty-eight hours after Ph. sergenti SGH injection, mice immunized with the above-men-
tioned plasmids were euthanized and IFN-γ and IL-5 cytokine expression was evaluated in
Fig 2. DTH and antibody responses to Ph. sergenti salivary proteins. BALB/c mice (six mice per group) were immunized in the right ear
three times at two week intervals with plasmids encoding for fourteen Ph. sergenti salivary proteins (10μg), Ph. sergenti salivary gland
homogenate (SGH, 0.5 pair), empty plasmid (VR1020, 10μg) or PBS (control) in total volume of 10 μl with PBS. Two weeks after the last
immunization, the contralateral ear was intradermal challenged with 0.5 pairs of Ph. sergenti SGH. Data shown are from one representative
of two independent experiments. (A) Delayed-type hypersensitivity response (DTH) generated at 48 h after Ph. sergenti SGH inoculation
was determined. (B) Total IgG antibody response to Ph. sergenti SGH was determined by ELISA in immunized BALB/c. Statistical
significance of the difference compared to the control empty-plasmid group (VR1020) is shown for each of the immunized groups. Dashed
line, the cut off value determined as the mean + 3 SD of the response of the empty-plasmid control group.
https://doi.org/10.1371/journal.pntd.0007067.g002
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their dLN by Real-time PCR (Fig 4). PsSP9 immunized mice was the only group that induced a
statistically significant increase in IFN-γ mRNA expression, compared to the control plasmid
group (median of fold change = 22.30, p = 0.04, Fig 4A, S2 Table), and was the group exhibit-
ing the lowest level of IL-5 (Fig 4B, S2 Table), which translated to the highest ratio of IFN-γ to
Fig 3. Histopathological analysis of the skin response to Ph. sergenti salivary proteins. Histological evaluation of representative
ears of BALB/c mice immunized with PsSP9, PsSP40, PsSP41, PsSP42, PsSP52, Ph. sergenti SGH, empty plasmid, or PBS. Two weeks
after the last immunization, mice were challenged in the opposite ear with Ph. sergenti salivary gland homogenate. Ear sections
stained with hematoxylin and eosin (H&E staining). Sections were analyzed by optical microscopy under 100× and 400× (A) or 100×
(B) magnification and the number of leukocytes enumerated microscopically. Bars represent the mean ±SD. Data are representative
of two independent experiments (3–5 mice per group). The p value is indicated for each immunized group compared with the
control plasmid group (VR1020).
https://doi.org/10.1371/journal.pntd.0007067.g003
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IL-5 expression (median of fold change = 17.12, p = 0.16, Fig 4C, S2 Table). In PsSP52-,
PsSP41- and PsSP42-immunized mice, IL-5 expression was significantly higher compared to
the control plasmid group (p<0.01 in PsSP52, p = 0.01 in PsSP41 and p = 0.03 in PsSP42, Fig
4B, S2 Table). Furthermore, neither the IFN-γ expression nor the ratio of IFN-γ/IL-5 expres-
sion in these groups was significantly different from the control plasmid group (Fig 4A and
4C, S2 Table). The data also revealed that there was no significant difference in terms of IL-5
and IFN-γ expression between the PsSP40-immunized mice and the control plasmid group
(Fig 4A and 4B, S2 Table). The exact p values and median (Q1-Q3) for the six tested samples
are presented in S2 and S3 Tables.
DNA immunization with the Ph. sergenti salivary molecule PsSP9 confers
protection against L. tropica in BALB/c mice
Based on the findings that the PsSP9-immunized group induced a Th1 immune response, we
examined whether immunization with DNA coding for PsSP9 salivary protein can lead to pro-
tection of animals against L. tropica infection. BALB/c mice were immunized intradermally in
their ears three times (with two-week intervals) with either Ph. sergenti SGH, plasmid encoding
a PsSP9 salivary protein, PBS, or empty plasmid. Two weeks after the last immunization, ani-
mals were challenged with metacyclic forms of L. tropica plus Ph. sergenti SGH. PsSP9-immu-
nized mice had significantly smaller nodules, indicated by ear thickness measurements,
compared to the control plasmid group which showed a significantly greater ear thickness
(Fig 5A, S4 and S5 Tables). The disease burden was determined based on the area under the
curves (AUC) as shown in Fig 5B. The data indicated that there was a significant reduction in
the disease burden after PsSP9 immunization, in comparison with the plasmid control group
(p = 0.02, Fig 5B, S6 Table).
Table 1. The immune response (DTH and antibody) induced in BALB/c mice by immunization with plasmids encoding for the most abundant secretory salivary
proteins of Ph. sergenti.
Sequence name Predicted molecular weight, kDa NCBI accession no. Protein annotation DTH response Antibody response
PsSP7 26.7 HM560864 D7-related – +
PsSP9 14 HM569364 PpSP15-like +++ –
PsSP14 17.1 HM560870 PpSP15-like – –
psSP15 14.7 HM560868 PpSP15-like – –
PsSP20 42.4 HM560866 yellow-related + +
PsSP26 43.9 HM569362 yellow-related +++ +++
PsSP40 35.6 HM560860 apyrase +++ –
PsSP41 33.7 HM560862 apyrase +++ –
PsSP42 35.9 HM560861 apyrase + –
PsSP44 22.5 HM569368 PpSP32-like +++ +++
PsSP52 29 HM537134 antigen 5-related +++ +
PsSP54 14.6 HM569365 PpSP15-like – –
PsSP73 12.2 HM569367 unknown – –
PsSP98 14.3 HM569366 unknown – –
SGH - - - – +++
VR1020 - - - – –
SGH, salivary gland homogenate; VR1020, empty plasmid.
(−) no response detected; (+) weak response, (+++) strong response
https://doi.org/10.1371/journal.pntd.0007067.t001
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Fig 4. Cytokine profile expression in the dLN of mice immunized with selected plasmids 48 h after Ph. sergenti SGH injection. BALB/c mice
(six mice per group) were intradermally injected in the right ear three times at two week intervals with plasmids encoding one of the five Ph.
sergenti salivary proteins (10μg), Ph. sergenti salivary gland homogenate (SGH, 0.5 pair), empty plasmid (VR1020, 10μg) or PBS alone in total
volume of 10 μl. Two weeks after the last immunization, the contralateral ear was intradermally challenged with 0.5 pairs of Ph. sergenti SGH. Data
shown are from one representative of two independent experiments. (A) IFN-γ, (B) IL-5 and (C) the ratio of IFN-γ to IL-5 mRNA expression in the
dLN of BALB/c mice immunized with PsSP9, PsSP40, PsSP41, PsSP44, PsSP52, empty plasmid, and PBS 48 h after challenge with Ph. sergenti SGH
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One-month post-infection, the parasite load in the ear of PsSP9-immunized mice was signif-
icantly lower than the control plasmid group (7.2×105 parasites in the control plasmid group
and 1.4×105 parasites in the PsSP9-immunized group, p = 0.02, Fig 5C, S7 Table). At two
months post challenge, the parasite load in the ear in PsSP9-immunized mice remained lower
than that in the plasmid control mice group, but the difference was not statistically significant
(1.0×106 parasites in control plasmid group and 2.7×105 parasites in PsSP9-immunized group,
p = 0.36, Fig 5D). The reduced parasite load correlated with the observed lower ear thicknesses
in PsSP9-immunized mice. SGH-immunized mice showed no significant differences in ear
thickness or disease burden compared to the control groups (Fig 5A and 5B, S4–S6 Tables). In
were analyzed. The obtained results were normalized to the expression level of HPRT. These data are presented as fold change relative to the PBS
control. The p value is indicated for each immunized group compared to the control plasmid group (VR1020).
https://doi.org/10.1371/journal.pntd.0007067.g004
Fig 5. The course of infection in PsSP9-immunized BALB/c mice after challenge with L. tropica plus Ph. sergenti SGH. BALB/c mice (ten mice per group)
were immunized in the right ear three times at two-week intervals with Ph. sergenti SGH, plasmid encoding PsSP9, empty plasmid (VR1020) or PBS. Two
weeks after the last immunization, mice were challenged with metacyclic L. tropica plus Ph. sergenti SGH in the contralateral ear. Data shown are from one
representative of two independent experiments. (A) The course of nodule development was monitored weekly by measuring ear thickness. Bars represent the
means ± SD). (B) Disease burden was calculated as the area under the curve (AUC) obtained from (A). Ear parasite loads were determined at (C) one and (D)
two months post-infection by Real-Time PCR (four to five mice per group). The p value in A, C and D are indicated for each vaccinated group compared with
control plasmid group (VR1020) and the p value in B is indicated for each groups compared with PsSP9 plasmid group.
https://doi.org/10.1371/journal.pntd.0007067.g005
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addition, at one and two month post-infection, there were no statistically significant differences
in the ear parasite burden in SGH-immunized mice compared with the control groups (Fig 5C
and 5D, S7 Table).
Protection from L. tropica infection in PsSP9-immunized mice correlates
with increased IFN-γ expression
The cytokine profile expression in the dLN was assessed at one and two months post-chal-
lenge. At one-month post-challenge, no significant differences in IFN-γ and IL-5 expression
levels or in the ratio of IFN-γ to IL-5 expression were observed in any of the groups (Fig 6A–
6C, S8 Table). At two months post-infection, IFN-γ expression was higher in the dLN of
PsSP9-immunized mice than in the control plasmid group, although the difference was not
statistically significant (median of fold change = 13.29, p = 0.05, Fig 6D, S9 Table). At this time
point, the expression of IL-5 in dLN of PsSP9-immunized mice was not different from that in
the control plasmid group (Fig 6E, S9 Table). Importantly, a significant increase in the ratio of
IFN-γ to IL-5 expression was observed in PsSP9-immunized mice compared with the control
plasmid group (median of fold change = 17.06, p = 0.04, Fig 6F, S9 Table). Exact p values and
median (Q1, Q3) for the 5 studied samples are presented in S4–S9 Tables.
Fig 6. Cytokine expression profile in the dLN of PsSP9-immunized mice a-t one and two months after L. tropica plus Ph. sergenti SGH challenge. BALB/c mice
(ten mice per group) were immunized in the right ear three times at two-week intervals with Ph. sergenti SGH, plasmid coding for PsSP9, empty plasmid (VR1020)
or PBS. Two weeks after the last immunization, mice were challenged with 107 metacyclic L. tropica plus Ph. sergenti SGH in the contralateral ear. Data shown are
from one representative of two independent experiments. (A) IFN-γ, (B) IL-5 and (C) the ratio of IFN-γ to IL-5 expression in the dLN of BAB/c mice (four to five
mice per group) immunized with PsSP9, Ph. sergenti SGH, VR1020 or PBS, at one month post-challenge with L. tropica plus Ph. sergenti SGH. The obtained results
were normalized to the expression level of HPRT. These data are presented as fold change relative to the PBS control group. (D) IFN-γ, (E) IL-5 and (F) the ratio of
IFN-γ to IL-5 mRNA expression in dLN of BALB/c mice (five mice per group) immunized with PsSP9, Ph. sergenti SGH, VR1020 or PBS, at two months post
challenge with L. tropica plus Ph. sergenti SGH. The obtained results were normalized to the expression level of HPRT. These data are presented as fold change
relative to the PBS control. The p value is indicated for each vaccinated group compared with the control plasmid group (VR1020).
https://doi.org/10.1371/journal.pntd.0007067.g006
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Discussion
It has been previously reported that bites of Ph. papatasi [13] and Ph. duboscqi [15,24], as well
as the injection of Ph. papatasi [7], Lu. longipalpis [17], and Lu. whitmani SGH [16], protected
rodents against leishmaniasis, manifested by reduced lesion size and decreased parasite bur-
den. Moreover, exposure to sand fly SGH has been reported to result in a DTH response
which is associated with the enhanced production of IFN-γ and IL-12 [13,37] or a higher IFN-
γ to IL-4 ratio [7]. The current study demonstrated that immunization with whole Ph. sergenti
SGH did not confer protection against L. tropica infection. Indeed, the ear thickness, disease
burden and parasite load in the Ph. sergenti SGH-immunized mice were similar to those of the
mice in the control groups. The lack of protection in the Ph. sergenti SGH-immunized mice
against infection correlates with a low ratio of IFN-γ to IL-5 production in the dLN during
infection. The current results were similar to the findings of Moura et al., who reported that
the immunization of BALB/c mice with Lu. intermedia SGH resulted in a non-protective Th2
immunity [38]. In contrast to whole SGH immunization, a single sand fly salivary protein
was shown to influence the outcome of leishmaniasis. Moura et al. observed that DNA immu-
nization with Lu. intermedia salivary protein Linb-11 resulted in an intense protective cell-
mediated immunity against infection with L. braziliensis [23] in contrast to the whole Lu. inter-
media saliva that exacerbated L. braziliensis infection [38].
The current results from our work also suggest that distinct Ph. sergenti salivary proteins
induce different immune responses. Immunization with 14 plasmids coding for Ph. sergenti
secreted salivary proteins resulted in the identification of 9 salivary proteins which produced
either a positive DTH response, an antibody response, or both responses in BALB/c mice
(Table 1). The triggering of a humoral immunity by such proteins is not necessary for anti-
leishmaniasis protection. As demonstrated by Gomes et al., LJM19 was the only saliva protein
that induced strong DTH in hamster without any detectable antibodies and DNA immuniza-
tion with this plasmid protected the animal against VL [19].
Salivary proteins that result in a Th1 type cellular immune response can be considered as
suitable candidate for producing an anti-leishmaniasis vaccine. In this study, the type of
immune response generated by the protective plasmid PsSp9 was characterized by a DTH
response with no detectable antibody response and a significantly high ratio of IFN-γ to IL-5
expression in the dLN compared to the control group. The current study reveals that DNA
immunization with the Ph. sergenti salivary protein PsSP7 can induce an antibody response,
but no detectable DTH response. Moreover, DNA immunization with PsSP41, PsSP42 and
PsSP52 produced a DTH response but induced high IL-5 expression in the dLN after Ph. ser-
genti SGH inoculation. Therefore, DNA immunization with these proteins shifted the immune
response to a Th2 type. Hence, application of such salivary proteins of Ph. sergenti (i.e. PsSP7,
PsSP26, PsSP41, PsSP42, PsSP44 and PsSP52) may exacerbate L. tropica infection or cause no
protective impact. Interestingly, DNA immunization with Ph. sergenti salivary protein PsSP9
(among the 14 tested Ph. sergenti salivary proteins) produced a DTH with high mononuclear
infiltration in the ear, a high ratio of IFN-γ to IL-5 expression in the dLN and no detectable
antibodies 48 h after Ph. sergenti SGH inoculation. Therefore, this protein directed the immu-
nity toward a Th1 response and was chosen as a candidate for producing an experimental vac-
cine against L. tropica.
The mice immunized with PsSP9 displayed a smaller ear thickness, lower disease burden,
and a lower parasite load in the ear in addition to a high IFN-γ to IL-5 expression ratio in the
dLN compared with the empty control plasmid group two months after challenge. The drain-
ing lymph node is a part of the immune system, where the induction of specific immunity
against an antigen occurs and where effector cells migrate to the skin and contribute to
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protection [39]. The protection observed in the PsSP9-immunized mice against CL can be
explained by the anti-PsSP9 immunity at the parasite transmission site in the ear dermis,
which may facilitate direct parasite killing by macrophage activation through IFN-γ. In fact,
IFN-γ acts to restrict Leishmania growth in macrophages of mice and humans as well as the
progression of leishmaniasis [40]. Vinhas et al. [41] demonstrated that the peripheral blood
mononuclear cells (PBMC) of individuals who were subjected to uninfected Lu. longipalpis
sand fly bites, exhibited IFN-γ expression after SGH stimulation. The production of IFN-γ was
also associated with L. chagasi parasite killing in a macrophage-lymphocyte autologous culture
[41]. This implies that after PsSP9 DNA immunization, the effector cells (IFN-γ+) might have
migrated to the site of L. tropica and Ph. sergenti SGH inoculation, activating the macrophages
and causing parasite killing which led to smaller lesions and reduced parasite load. The pres-
ence of an immune response against PsSP9 at the site of the parasite plus SGH injection in the
dermis of the ear may act as an adjuvant to accelerate the triggering of a proper host immune
response against Leishmania. Macrophage activation induces inflammatory responses and pre-
vents the growth of Leishmania [42] by increasing the production of ROS, antigen presentation
and maturation of phagosome [43]. After taking the L. tropica parasite and transporting the
antigen, macrophages and Langerhans cells migrate and then differentiate into the APCs
within the LNs and trigger a DTH response by CD4 expressing T cells. According to the find-
ings of Oliveira et al., the immune response caused by the salivary protein induces a protective
immunity against Leishmania. The DNA immunization of mice with PpSP15 resulted in a Th1
immunity against L. major [20]. In the current study, it was also hypothesized that DNA
immunization with PsSP9 may act similarly. Only two critical cytokines in the dLN of immu-
nized mice were analyzed (i.e. IFN-γ and IL-5). Further investigation of early time points in
the dLN and the ear skin at the site of parasite challenge are needed to determine precisely the
contribution of anti-saliva immunity in direct parasite killing and its indirect role in accelerat-
ing the induction of immunity against Leishmania.
It is noteworthy that as a PpSP15-like protein family member, the PsSP9 is related to a sali-
vary protein (14 kDa) which has no structural or sequential homology to identified proteins in
humans or other organisms. PsSP9 protein is closely similar to PpSP12 (70% identity), PdSP14
(69% identity), PpSP14 (51% identity) and PpSP15 (46% identity) salivary proteins. PpSP15
was the first salivary protein considered as a candidate for an anti-leishmaniasis vaccine [21].
Oliveira et al. showed that DNA immunization of mice with PpSP15 triggered a DTH response
and induced high levels of IL-12 and IFN-γ expression 2h post exposure to Ph. papatasi bites
[20,21]. This immune response was associated with the accelerated induction of an immunity
and protection against Leishmania [20,21]. Recently, DNA immunization with PdSP15 from
Ph. duboscqi salivary protein, as a member of the PpSP15 family, was demonstrated to protect
non-human primates against L. major which was delivered through the bite of an infected
sand fly [24]. Furthermore, PdSP15 has been reported to exhibit immunogenic characteristics
in humans, considering that PdSP15 was recognized by PBMC and sera in individuals exposed
to the bites of Ph. duboscqi [24]. In this regard, it is suggested that among different Ph. sergenti
salivary proteins, PsSP9 would be a better inducer of a Th1 protective immune response in a
mouse model. Further investigations are still required to assess the immunogenic characteris-
tics of PsSP9 as a recombinant protein vaccine for mice and whether it exhibits immunogenic-
ity in human subjects, so as to be nominated as a potential candidate or as a component of a
human anti-leishmaniasis vaccine.
In summary, the current study demonstrated that while the whole Ph. sergenti SGH did not
induce any protective immune response against L. tropica infection, a particular salivary pro-
tein from Ph. sergenti, PsSP9, induced a powerful protection against L. tropica in BALB/c mice.
These findings highlight the application of specific salivary proteins from sand flies in anti-
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leishmaniasis vaccination approaches, which would be improved when used in combination
with a Leishmania antigen and/or another prophylactic agent.
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